Abstract：
This chapter will describe a method for measuring endogenous and infused Factor VIII (FVIII) in patients on emicizumab therapy (Hemlibra, Genetec, Inc). Emicizumab is a bispecific monoclonal antibody used in patients with hemophilia A, with or without inhibitors. The mechanism of action for emicizumab is novel and mimics the role that FVIII plays in vivo by binding and bridging FIXa and FX. It is vital that the laboratory understands the effect this drug has on coagulation tests and uses a suitable chromogenic assay which is not affected by emicizumab, for determination of FVIII coagulant activity and inhibitors.
摘要：
本章将描述一种方法，用于测量使用emicizumab治疗的患者的内源性和输注因子VIII（FVIII）（Hemlibra，Genetec,公司）。Emicizumab是一种用于血友病A患者的双特异性单克隆抗体，有或没有抑制剂。emicizumab的作用机制是新颖的并且模拟FVIII通过结合和桥接FIXa和FX在体内发挥的作用。至关重要的是，实验室了解这种药物对凝血测试的影响，并使用不受emicizumab影响的合适的显色测定法，用于测定FVIII促凝剂活性和抑制剂。
